UPDATE: COVID-19 Read the Message

Press Releases

The press releases contained in this archive section are provided for historical purposes only. The information contained in each press release is accurate only as of the date each press release was originally issued. PTC Therapeutics disavows any obligation to update the information contained in such press releases after the date of their issuance.

Date Title and Summary View
Feb 25, 2021
- $333 million 2020 total net product revenue representing 14% year-over-year growth - - Advancing multiple registration-directed clinical trials - - PTC518 healthy volunteer data expected in the first half of 2021 for Huntington disease program - - 2021 DMD franchise revenue guidance reaffirmed at
Additional Formats
Feb 24, 2021
-- Results found that patients treated with Evrysdi at 12 months demonstrated significant improvements in survival and developmental milestones -- -- The U.S. Food and Drug Administration approved Evrysdi in August 2020 as the first and only at home SMA treatment with proven efficacy in adults,
Additional Formats
Feb 17, 2021
-- PTC299 is an oral therapy that has a novel dual mechanism of action that inhibits viral replication and attenuates the uncontrolled inflammatory response -- -- Stage 1 of the clinical trial is complete -- SOUTH PLAINFIELD, N.J. , Feb. 17, 2021 /PRNewswire/ --  PTC Therapeutics, Inc.  (NASDAQ:
Additional Formats
Feb 16, 2021
SOUTH PLAINFIELD, N.J. , Feb. 16, 2021 /PRNewswire/ --  PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that management will present a company overview at the following conferences: Raymond James 42 nd Annual Institutional Investors Conference Tuesday, March 2 nd at 7:30 a.m.
Additional Formats
Feb 11, 2021
SOUTH PLAINFIELD, N.J. , Feb. 11, 2021 /PRNewswire/ --  PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the Company will host a webcast conference call to report its fourth quarter and year-end 2020 financial results and provide an update on the company's business and outlook on
Additional Formats
Feb 04, 2021
SOUTH PLAINFIELD, N.J. , Feb. 4, 2021 /PRNewswire/ --  PTC Therapeutics, Inc.  (NASDAQ: PTCT) will host a conference call today at 5:30 p.m. E.T. to review results from its clinical study 045 of Translarna™ (ataluren) in patients with nonsense mutation Duchenne muscular dystrophy.
Additional Formats
Jan 14, 2021
- New category targets programs that support the transition from adolescence to adulthood - - Proposal submissions for 2021 STRIVE Awards are due March 15, 2021 - SOUTH PLAINFIELD, N.J. , Jan. 14, 2021 /PRNewswire/ --  PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the launch of the seventh
Additional Formats
Jan 13, 2021
SOUTH PLAINFIELD, N.J. , Jan. 13, 2021 /PRNewswire/ -- PTC Therapeutics , Inc. (NASDAQ: PTCT) today announced that on January 6, 2021 it approved non-statutory stock options to purchase an aggregate of 13,465 shares of its common stock and 4,665 restricted stock units ("RSUs"), each representing
Additional Formats
Jan 11, 2021
- ~$333 million preliminary unaudited 2020 total net product revenue representing 14% year-over-year growth - - Huntington splicing program healthy volunteer data expected 1H 2021 - - Multiple late-stage clinical programs advancing with six registration-directed trials - - 2021 Duchenne franchise
Additional Formats
Jan 04, 2021
SOUTH PLAINFIELD, N.J. , Jan. 4, 2021 /PRNewswire/ --  PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that management will present a company update at the 39th Annual J.P. Morgan Healthcare Conference on Monday, January 11 th at 7:30 a.m. EST .
Additional Formats